Share this to:

Support & Insight for the Autumn of Life

A4 Trial Getting Closer to a Cure


The 3-year A4-Trial is using solanezumab to slow memory loss caused by Alzheimer’s. See how this government-sponsored nationwide trial is making important new progress in the search for an Alzheimer’s cure.

The purpose of the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study” for short) is to test whether a new investigational treatment, called an anti-amyloid antibody, can slow memory loss caused by Alzheimer’s disease.

Continued below video…

Amyloid is a protein normally produced in the brain that can build up in older people, forming amyloid plaque deposits. Scientists believe this buildup of deposits may play a key role in the eventual development of Alzheimer’s disease-related memory loss. The overall goal of the A4 study is to test whether decreasing amyloid with antibody investigational treatment can help slow the memory loss associated with amyloid buildup in some people.

The A4 study invites older individuals (ages 65-85) who have normal thinking and memory function but who may be at risk for memory loss due to Alzheimer’s disease, but have no outward signs of the disease to participate in the study. We seek to enroll 1,000 adults who have an “elevated” level of amyloid plaque in their brain. Physicians and researchers will use an imaging test called a PET scan to determine whether a potential participant has evidence of this plaque buildup. People who do not show evidence of elevated amyloid in their brains will not be able to participate, but may be asked to participate in a separate study. This group will not receive the investigational drug or placebo (i.e., an inactive substance designed to mimic the appearance of a drug), but will complete the same memory tests every six months to compare changes in cognition over time.

The A4 study lasts for three years, and participants will be required to visit the clinical research site once a month. Participants will be assigned at random to receive either the investigational drug or a placebo and will be monitored over the course of the three years. All clinical studies, including the A4 study, may involve some risks associated with participation. If you are considering participating in A4, you will have detailed discussions with physicians and research staff regarding the investigational treatment and other aspects of the A4 study.

Who is sponsoring the study?

The A4 study is a landmark public-private partnership, funded by the National Institute on Aging, Eli Lilly and Company, and several philanthropic organizations. The A4 trial is coordinated by the University of Southern California’s Alzheimer’s Therapeutic Research Institute, with study sites in multiple locations.


Notify of

1 Comment
Inline Feedbacks
View all comments
June 24, 2016 7:38 pm

Searching in Google with the words "solanezumab failure",we can find scientific articles that shows that this "old failed drug" the solanezumab,do not works.For example the scientific article published in the New England Journal of Medicine, 2014" with the title:"Phase 3 Trials of Solanezumab for Mild l-to-Moderat Alzheimer's disease.Authors: Doody and colleagues,from the Alzheimer's Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston ,U.S.A. ,where we can read% "Solanezumab, a humanized monoclonal antibody,that binds amyloid, FAILED to improves cognition or functional ability.
But there ate lots of texts in Google, about the solanezumab failures.

B. Berger

B. Berger

Visit Our Pages On:


This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor


Fish, Omega-3, Dementia
Dr. Michael Gregger, Director of the authoritative NutritionFacts site, asks, "Why has fish consumption been associat...
Is Sitting Bad for the Brain? Maybe Not.
Is keeping seated and sedentary, while intellectually stimulated, part of the best way to care for your brain?
dna, biology, medicine
The Genetic Factor That Fends Off Alzheimer's
A massive study of medical and genetic data shows that people with a particular version of a gene involved in immune...
Would love your thoughts, please comment.x
News, Treatments, Care Tips

Subscribe To The Weekly Newsletter

videos & articles on Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter